TECHWIRE 30
(CIX: WRAL30)  1,099.18  up arrow+0.52  (0.05 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Apple)  100.58  up arrow+0.01  (0.01 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: QUINTILES)  56.34  up arrow+0.29  (0.52 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: BASF SE)  102.70  up arrow+1.23  (1.21 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: BioCryst)  12.61  down arrow-0.48  (-3.67 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: BioDelivery)  13.46  down arrow-0.43  (-3.1 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: CEMP)  9.37  down arrow-0.12  (-1.26 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Cisco Systems)  24.89  up arrow+0.18  (0.73 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Cree)  45.07  down arrow-0.32  (-0.71 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: DARA)  1.25  down arrow-0.02  (-1.51 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: EMC CORPORATION)  29.62  down arrow-0.08  (-0.27 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Extreme Networks)  5.23  down arrow-0.05  (-0.95 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: FB)  74.57  down arrow-0.24  (-0.32 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: GLAXOSMITHKLINE)  47.70  down arrow-0.11  (-0.23 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: GOOG)  583.37  down arrow-1.12  (-0.19 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: IBM)  191.23  up arrow+1.13  (0.59 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NY: LH)  106.82  up arrow+0.67  (0.63 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: Lenovo Group)  30.65  up arrow+0.31  (1.01 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: MRK)  58.85  down arrow-0.63  (-1.06 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Microsoft Corp)  45.22  up arrow+0.27  (0.6 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: NTAP)  40.92  down arrow-0.05  (-0.11 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: NOVARTIS AG)  88.95  up arrow+0.35  (0.4 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: Novozymes A/S)  44.87  down arrow-0.25  (-0.55 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: PFIZER)  28.82  down arrow-0.07  (-0.24 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Pozen)  7.72  up arrow+0.07  (0.92 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: RED HAT)  61.57  down arrow-0.11  (-0.18 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: BBRY)  9.85  down arrow-0.32  (-3.1 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Salix)  158.30  up arrow+1.12  (0.71 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: SQI)  15.06  down arrow-0.09  (-0.59 %)  Updated: 08:10 PM EDT, Aug 21 2014

Posts tagged “Aurora”

Updated January 6

Premium Lock Two new investors help Metabolon raise $15M

Metabolon, whose proprietary technology has applications in medical diagnostics as well as food and nutrition, is getting a financial boost from two new investors as well as six existing ones in its new round of funding.

Metabolon’s “Analytical Platform”: Metabolon’s “Analytical Platform”:

Updated April 30, 2013

Premium Lock Another RTP biotech company files to go public

Going public An emerging biotech company focused on drugs to control bleeding is the latest firm with major operations and links to the Triangle to seek to go public. WRALTechWire Insiders can find out more.

December 20, 2012

Premium Lock Regado Biosciences, which bases lab in Durham, raises $51M

Triangle-based Aurora Funds is among the participants in the latest round of funding for Regado, which is developing DNA-based blood treatments.

DNA   DNA

December 19, 2012

Premium Lock Triangle VC's prediction for 2013 reflects a changing industry

Hold on to your dollars The venture capital industry continues to change, with fewer firms doing business in 2013 yet fund raising to remain stable or increase in some cases.

Updated November 14, 2012

Premium Lock Chapel Hill drug startup Cardioxyl confirms $28M in venture funding

Cardioxyl Cardioxyl Pharmaceuticals, which is backed by Aurora Funds, is developing a treatment for heart failure. The company lands a new investor and adds two MDs to its board.

November 7, 2012

Premium Lock Chapel Hill drug firm Cardioxyl raises $28M in venture funding

Cardioxyl Cardioxyl Pharmaceuticals, which is backed by Aurora Funds, is developing a treatment for heart failure.

August 20, 2012

Premium Lock Chemical testing firm Centice raises $1M in debt financing

Police and narcotics officials can use Centice devices to identify controlled prescription drugs and illegal narcotics. Centice this year released a mobile narcotics identification system that law enforcement can use in the field.

Cetnice's PASS Rx Cetnice's PASS Rx

April 24, 2012

Premium Lock Argos Therapeutics raises $25M after withdrawing IPO

The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.

Argos process Argos process

Updated April 6, 2012

Premium Lock Nanotech startup funding: What investors are looking for

Nanotech companies are clamoring for financing at a time when investor purse strings remains tight. Some investors are showing interest in nanotechnology investments, but that interest doesn't mean that they approach these deals with any less caution.

Nanotech conference Nanotech conference

Updated February 16, 2012

Premium Lock Argos Therapeutics aims for as much as $79M in IPO

The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.

Argos process Argos process

February 10, 2012

Premium Lock $40M Aldagen deal is no quick exit for its investors

Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.

Aldagen's pipeline Aldagen's pipeline

Updated February 9, 2012

Premium Lock Durham stem cell firm Aldagen sold for up to $40M

Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.

A purified STEM cell A purified STEM cell

October 28, 2011

Premium Lock HyperBranch Medical raises $1M in new funding

HyperBranch The financing for the Durham-based firm that is backed by The Aurora Funds follows a $2.1 million fundraising nearly a year ago. Six existing investors in the company participated in the latest offering,

Updated August 29, 2011

Premium Lock Metabolon lands $13.1M in fourth round of venture financing

The Triangle-based company, which focuses on biomarker technology, secures a new investor. Local venture firm Aurora Funds also is an investor.

Metabolon’s “Analytical Platform”: Metabolon’s “Analytical Platform”:

Updated July 29, 2011

Premium Lock Argos Therapeutics files for $86M initial public offering

The Durham-based biopharmaceutical firm focuses on individualized therapies targeting cancer, HIV and infectious diseases. Its investors include Intersouth Partners and Aurora Funds.

Argos process Argos process

July 12, 2011

Premium Lock Stem cell-focused Aldagen raises $1.1M in funding

The Durham-based company recently withdrew plans for an $80 million stock offering.

A purified STEM cell A purified STEM cell

July 1, 2011

Premium Lock Durham-based Regado Biosciences closes on $26M in new financing

DNA The company, which raised $23 million in 2007, has been working on its new round since 2009. Regado is developing a DNA-based system to control bleeding.

Updated May 31, 2011

Premium Lock Chemical tech firm Centice raises $2.3M in new funding

The Morrisville-based company, which reorganized its management in 2009, says the funds will be used to drive growth of existing, new chemical verification and identification products.

Cetnice's PASS Rx Cetnice's PASS Rx

Updated April 27, 2011

Premium Lock Roll this: Video tech firm Digitalsmiths raises $12.5M

The Durham-based startup sometimes touted as the "Google of video" is growing face, developing more technology that's finding increasing demand in the online video archiving space.

Clip from "Top Gun" as tagged by Digitalsmiths Clip from "Top Gun" as tagged by Digitalsmiths

Updated April 5, 2011

Premium Lock Stem cell firm Aldagen withdraws planned $80.5M IPO

The Durham-based life science company cites "market conditions" as the reason for the pullback. It's the second time that the company, which is backed by Triangle venture firms Intersouth and Aurora, has cancelled an IPO.

A purified stem cell A purified stem cell

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll